Redeye has revised its estimates for Modelon following the Q1 2024 report and the announced rights issue, conditional on the approval of the extraordinary general meeting on June 7. The most important highlight in the report was Modelon Impact’s accelerating growth, in combination with an optimistic management regarding the customer pipeline.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/